Results 11 to 20 of about 4,410 (137)
Asymmetric Graves’ Orbitopathy [PDF]
Frontiers in Endocrinology, 2020 Graves’ Orbitopathy (GO) is an autoimmune orbital disorder usually presenting as a sequala of autoimmune thyroid disease. The presence of GO is associated with increased psychological burden and, in severe cases may cause blindness.
Grigorios Panagiotou, Petros Perros
doaj +3 more sources
Orbital Signaling in Graves’ Orbitopathy [PDF]
Frontiers in Endocrinology, 2021 Graves’ orbitopathy (GO) is a complex and poorly understood disease in which extensive remodeling of orbital tissue is dominated by adipogenesis and hyaluronan production.
Mohd Shazli Draman +4 more
doaj +5 more sources
Sirolimus for the treatment of Graves' orbitopathy. [PDF]
Thyroid ResA role of mTOR (mammalian target of rapamycin) in the pathogenesis of Graves' Orbitopathy (GO) has been proposed and rapamycin, better known as sirolimus, an mTOR inhibitor, was recently used in patients with GO. Here we review the available studies evaluating the role of mTOR in GO pathogenesis and the effects of sirolimus on GO.A comprehensive search
Comi S +4 more
europepmc +4 more sources
Steroid-resistant Graves' orbitopathy: Therapeutic options [PDF]
Medicinski Glasnik Specijalne Bolnice za Bolesti Štitaste Žlezde i Bolesti Metabolizma "Zlatibor", 2023 Graves orbitopathy is the most common extrathyroidal manifestation of autoimmune hyperthyroidism, although it can rarely occur in euthyroid and hypothyroid patients.
Klet Sanja +6 more
doaj +1 more source
Frontiers in Endocrinology, 2022 BackgroundImmunosuppressive therapy of Graves’ orbitopathy (GO) is indicated during the active phase of disease. Intravenous steroids (IVGC) are effective in about 70% of patients, although unresponsiveness or relapse are observed.
Irene Campi +16 more
doaj +1 more source
IgG4 as a Biomarker in Graves’ Orbitopathy [PDF]
Mediators of Inflammation, 2021 Immunoglobulin G4‐related disease (IgG4‐RD) is a chronic inflammatory disorder associated with fibrosis and abundant tissue lymphoplasmacytic infiltrations. It typically affects the pancreas, the salivary glands, and the retroperitoneal space. However, it might also involve multiple other organs, including the orbit and the thyroid. Recent studies have
Michał Olejarz +5 more
openaire +3 more sources
Microbiome and Graves’ Orbitopathy [PDF]
European Thyroid Journal, 2020 <b><i>Background:</i></b> Studies from animal models of autoimmunity have highlighted the potential importance of microorganisms and their metabolic products in shaping the immune system. <b><i>Summary:</i></b> This review provides an introduction to the current state-of-the-art in microbiome research ...
Giulia, Masetti, Marian, Ludgate
openaire +2 more sources
Ophthalmology, 2007 Preface: Wiersinga, W.M. Kahaly, G.J. Diagnosis and Pathogenesis Clinical Manifestations: Dickinson, A.J. Orbit-Thyroid Relationship: Lazarus, J.H. Marino, M. Epidemiology: Daumerie, C. Kalmann, R. Pathogenesis: Orgiazzi, J. Orbital Imaging: Pitz, S. Diagnosis and Differential Diagnosis of Graves' Orbitopathy: Mourits, M.P.
Aparna, Bhatnagar +4 more
+7 more sources
The Amsterdam Declaration on Graves' Orbitopathy [PDF]
Thyroid, 2010 For decades, clinicians who manage patients with Graves’ orbitopathy (GO) have been anticipating the emergence of new effective therapies for the management of this condition. That dream has yet to come true, but it has become apparent that conventional treatments such as steroids and surgery, when applied at the appropriate time and by centres that ...
Perros, P., Wiersinga, W.M.
openaire +4 more sources